Epigenetic Regulation: Histone Modifications, Transcription, and Disease

Context from lecture:
- Epigenetic modifications regulate gene expression without changing the DNA sequence.
- Focus on histone modifications: acetylation and methylation; roles of HATs, HDACs, histone methyltransferases (HMTs), and demethylases; also mention DNA methylation.
- Modifications are reversible and influence chromatin accessibility for transcriptional machinery.
- Epigenetic changes can affect many genes and pathways, so small alterations can have large downstream effects (e.g., in disease).
Immediate classroom point about neurotransmitters and diet:
- Question asked: if some amino acids come from the diet and are necessary for certain neurotransmitters, does fasting or malnutrition alter neurotransmitter synthesis balance?
- Answer anticipated: likely a small effect under normal conditions due to physiological compensation, but malnutrition could cause larger problems.
- Course references: nutritional neuroscience and neurobiochemistry courses (mentioned as sources for deeper answers).
Core concept: chromatin structure and regulation by post-translational modifications (PTMs) on histones
- DNA is wrapped around nucleosomes; accessibility of DNA to transcription machinery depends on how tightly histones are associated with DNA.
- There must be intermediate states of openness, not just fully closed (heterochromatin) or fully open (euchromatin).
- PTMs act as tags or switches that modulate these states and the activity of transcriptional complexes.
Histone acetylation and deacetylation (HATs and HDACs)
- Histone acetyltransferases (HATs) add acetyl groups to lysine residues (and sometimes arginine) on histone tails.
- Acetylation neutralizes positive charge on lysine, reducing DNA–histone affinity and promoting a more relaxed, open chromatin state.
- Histone deacetylases (HDACs) remove acetyl groups, promoting a more closed chromatin state.
- Acetylation is reversible; the balance of HAT and HDAC activity determines local chromatin accessibility.
- Inhibitors of HDACs (HDAC inhibitors) can increase transcription by maintaining acetylation; this has implications in disease contexts.
Mechanistic view of the nucleosome and chromatin openness
- Chromatin regulation is not binary; there are multiple intermediate states to allow region-specific access at different times.
- Transcriptional activation requires that the chromatin be sufficiently open for RNA polymerase II and transcription factors to access promoter regions.
Role of HATs, HDACs, and coactivators in transcription initiation
- HAT activity is present in standalone enzymes and also in regions of other proteins (coactivators) that target specific promoters.
- CREB-binding protein (CBP) is a key coactivator with a HAT domain; it helps acetylate histones and open chromatin.
- CREB pathway as a concrete example:
- Signaling through adenylyl cyclase increases cyclic AMP (cAMP).
- cAMP activates Protein Kinase A (PKA).
- PKA phosphorylates CREB, enabling CREB to bind to DNA at CRE elements (CREs) in promoters.
- CREB recruits CBP, whose HAT activity acetylates histones, opening chromatin and enabling transcription initiation.
- The CREB-CBP axis illustrates how signaling pathways feed into transcriptional activation.
- The transcription initiation complex also includes transcription factors and often enhancers; opening chromatin is a prerequisite but not the sole determinant of transcription.
Promoter architecture and DNA accessibility
- CREB binds to CREs in promoters/enhancers to regulate transcription; promoter elements such as the TATA box help initiate transcription.
- TATA box basics:
- TATA consists of thymine–adenine pairs, which form two hydrogen bonds, making these regions easier to unwind for transcription initiation.
- In contrast, GC-rich regions form three hydrogen bonds and are more stable.
- The diagrammatic representation shows CBP with an HAT domain that acetylates histones (not DNA directly) to loosen the chromatin around promoter regions so the transcription initiation complex can assemble.
- The promoter region often contains a CRE (CREB response element) and can be modulated by multiple transcription factors (e.g., SP1, c-Fos, etc.) that can cooperate to increase transcription levels.
- Mutation in promoter regions or response elements can reduce transcription by decreasing factor binding affinity; not always an all-or-nothing effect but can dampen transcriptional output.
Dimmer-switch view of transcription control
- Transcription is best viewed as a dimmer switch rather than a simple on/off switch; many factors (coactivators, co-repressors, signaling strength) modulate the final transcription level.
- The amount of PKA signaling, CREB phosphorylation, CBP availability, and recruitment of additional transcription factors all contribute to the final transcription level.
- Signals can be tonic (low baseline activity) and are often modulated up or down in response to stimuli.
Transcription factors, redundancy, and mutation consequences
- Transcription factors (e.g., estrogen receptor) require signaling to become activated (e.g., estrogen binding triggers receptor dimerization, nuclear translocation, DNA binding).
- There are multiple receptor types for a given signal (e.g., estrogen receptor alpha and beta; metabotropic receptors) that can have distinct effects; losing one receptor type does not always abolish signaling but can alter outcomes.
- Mutations such as premature stop codons can produce truncated receptors that bind hormone but cannot interact with DNA and thus cannot drive transcription.
- Signaling specificity matters: different receptor subtypes yield different downstream effects even for the same hormone.
- The concept of backup mechanisms exists, but the extent of redundancy depends on the specific signaling pathway.
Epigenetic marks: euchromatin vs heterochromatin
- Euchromatin: loosely packed, transcriptionally active regions; historically associated with higher acetylation.
- Heterochromatin: tightly condensed, transcriptionally inactive regions; associated with higher methylation in many contexts.
- Expected acetylation patterns:
- Euchromatin: higher acetylation due to open chromatin facilitating transcription.
- Heterochromatin: lower acetylation, more compact structure.
- Methylation patterns are more nuanced; methylation of histones generally correlates with repression, but the outcome depends on the specific residue and methylation state.
Histone methylation and histone methyltransferases (HMTs)
- Methylation on histones occurs on lysines (and sometimes arginines) and is catalyzed by histone methyltransferases (HMTs).
- General rule discussed: increased histone methylation tends to repress transcription by promoting tighter nucleosome interactions and chromatin compaction.
- Specific residues and patterns matter:
- Lysine residues commonly studied include those at positions K4, K9, and K27 on histone H3 (denoted as H3K4, H3K9, H3K27).
- In many contexts, methylation at these sites correlates with different transcriptional outcomes, but the same methylation mark can have different effects depending on the site and the number of methyl groups (me1, me2, me3).
- Methylation states can be mono-, di-, or tri-methylated:
- Me1, Me2, Me3 on a given lysine can signal different binding partners and regulatory outcomes.
- HMTs and demethylases collaborate to regulate these marks; DNA methylation also plays a role in gene regulation but is a distinct layer.
- Notable gene: EHMT1 is a histone methyltransferase that targets H3K9 (H3K9 methylation).
- EHMT1 is implicated in development and disease (e.g., Sotos syndrome) when disrupted.
- H3K9 methylation and EHMT1 usage: a specific example highlighting the role of histone methylation in disease contexts.
DNA methylation vs histone methylation
- While the discussion emphasized histone methylation, DNA methyltransferases (DNMTs) also regulate DNA methylation as another layer of epigenetic control.
- Distinguish between histone methylation (on histone tails) and DNA methylation (on cytosines, typically in CpG context) as two separate, but interacting, epigenetic mechanisms.
Transcriptional coactivators, regulators, and domain architecture
- Coactivators can be standalone enzymes or domains within larger proteins (e.g., CBP contains an HAT domain).
- Domains such as KIX enable interactions with transcription factors like CREB, enabling proper assembly of the initiation complex.
- Notation and domain mapping (e.g., linear amino acid sequence vs three-dimensional folding) illustrate how mutations in specific domains affect function:
- HAT domain mutations can reduce histone acetylation activity.
- Interaction domains (e.g., those that bind CREB) can disrupt assembly of the transcriptional machinery.
- The three-dimensional structure and domain architecture determine interactions, catalytic activity, and ultimately gene regulation.
Disease contexts and therapeutic implications
- Cancer: misregulation of histone acetylation and methylation can disrupt transcription control and cell division; mutations in histones or modifying enzymes can have widespread effects.
- Neuronal disease and aging:
- HDAC inhibitors have shown neuroprotective effects in some contexts, though side effects arise from global action and non-targeted targeting.
- Alzheimer’s disease pathology has been linked to dysregulated histone acetylation; directly targeting HDACs or acetylation states is an active area of research.
- There is interest in increasing HAT activity or delivering inhibitors/activators to specific brain regions (e.g., hippocampus) to target disease processes more precisely.
- Sotos syndrome (note on EHMT1): a developmental disorder characterized by excessive growth at birth and distinctive facial features; nonprogressive neurological manifestations suggest early developmental misregulation of histone methylation patterns, particularly H3K9 methylation via EHMT1.
- Aging and cognitive function:
- Neurological function tends to peak in the late twenties; myelination continues to mature into the mid- to late-20s (~24–25 years).
- After around age 30, there is a general decline in many neural functions, and aging involves global chromatin changes that affect gene regulation.
- Evolutionary note: natural selection acts at reproductive ages, so many aging-related changes are not strongly selected against.
- Practical considerations in therapy:
- Targeted therapies (selective HDACs or HATs) may minimize side effects compared to broad-acting inhibitors.
- Delivering therapies to specific brain regions or cell types could improve efficacy and reduce off-target effects.
Summary of key terms and concepts
- Histone acetylation: mediated by HATs; opens chromatin; promotes transcription.
- Histone deacetylation: mediated by HDACs; closes chromatin; represses transcription.
- CBP: CREB-binding protein; coactivator with HAT activity; links signaling to chromatin opening.
- CREB: cAMP response element-binding protein; activated by phosphorylation via PKA downstream of G protein-coupled receptor signaling.
- CRE: CREB response element; DNA sequence where CREB binds to regulate transcription.
- TATA box: promoter element with AT-rich region facilitating initiation due to fewer hydrogen bonds between AT base pairs vs GC.
- Promoter architecture: transcription factors, enhancers, CREB, CBP, and other coactivators collaborate to modulate transcription levels.
- Methylation (histone): generally represses transcription; relies on specific residues and methylation states (me1/me2/me3).
- H3K9 methylation: a well-studied site associated with repression; EHMT1 is a key enzyme for this mark.
- H3K4 methylation: another common site discussed in the context of methylation (noted as K4 in the transcript).
- Demethylases: enzymes that remove methyl marks from histones.
- DNA methylation: a separate, interacting layer of epigenetic regulation.
- Sotos syndrome: EHMT1-related developmental disorder highlighting the importance of histone methylation in development.
- Aging and myelination: neural maturation continues after adolescence, with aging bringing declines in cognitive function and changes in chromatin marks.
Final note and forward look
- The lecture foreshadows more on DNA methylation and noncoding RNAs (microRNAs) in future sessions.
- Emphasis on understanding mechanisms to reason about interventions: which enzyme to target, what the downstream effects would be, and how specificity matters for therapeutic strategies.
Quick reference points (LaTeX-formatted cues)
- Histone marks and nomenclature: ext{H3K4me3}, ext{H3K9me3}, ext{H3K27me3} (examples of methylation states on histone H3).
- Methylation states: me1,~me2,~me3 for lysine residues.
- Lysine residues on histones: K4,~K9,~K_{27} (context: H3K4, H3K9, H3K27).
- EHMT1: ext{EHMT1} (histone methyltransferase targeting ext{H3K9}).
- TATA-box chemistry: AT base pairs form 2 hydrogen bonds; GC form 3 hydrogen bonds.
- Signaling cascade example: G_{\alpha s}
  ightarrow ext{adenylyl cyclase}
  ightarrow ext{cAMP}
  ightarrow ext{PKA}
  ightarrow ext{CREB phosphorylation}
  ightarrow ext{CBP/HAT}
  ightarrow ext{histone acetylation}
  ightarrow ext{transcription}.

Epigenetic regulation modulates gene expression without altering the DNA sequence, primarily through reversible histone modifications like acetylation and methylation. These modifications dictate chromatin accessibility, influencing whether DNA regions are open (euchromatin) for transcription or condensed (heterochromatin) and inactive.

Histone acetyltransferases (HATs) add acetyl groups to histone lysines, neutralizing their positive charge, which loosens chromatin and promotes transcription. Conversely, histone deacetylases (HDACs) remove acetyl groups, leading to chromatin compaction and transcriptional repression. This dynamic balance acts as a "dimmer switch" for gene expression. For example, in the CREB pathway, signaling via cyclic AMP (cAMP) activates Protein Kinase A (PKA), which phosphorylates CREB. Phosphorylated CREB then recruits CREB-binding protein (CBP), a coactivator with HAT activity, to promoter regions containing CRE elements and TATA boxes (AT-rich and easily unwound regions), leading to histone acetylation and transcription initiation.

Histone methylation, catalyzed by histone methyltransferases (HMTs), generally represses transcription by tightening chromatin. Specific marks like ext{H3K9} methylation are associated with repression, with EHMT1 being a key enzyme implicated in developmental disorders such as Sotos syndrome. DNA methylation is a distinct, yet interacting, layer of epigenetic control.

Misregulation of these epigenetic processes is linked to diseases including cancer, neurodegenerative disorders like Alzheimer's disease, and aging. Therapeutic strategies involving targeted histone-modifying enzymes, such as HDAC inhibitors, are being explored for their potential to restore proper gene expression and mitigate disease, with a focus on achieving specificity to minimize off-target effects.